346 related articles for article (PubMed ID: 27275637)
41. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma.
Park S; Moon SH; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Ahn HK; Lee JY; Kim SJ; Choi JY; Kim WS
Am J Hematol; 2012 Sep; 87(9):937-40. PubMed ID: 22730093
[TBL] [Abstract][Full Text] [Related]
42. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.
Wöhrer S; Jaeger U; Kletter K; Becherer A; Hauswirth A; Turetschek K; Raderer M; Hoffmann M
Ann Oncol; 2006 May; 17(5):780-4. PubMed ID: 16497824
[TBL] [Abstract][Full Text] [Related]
43. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
Ng AP; Wirth A; Seymour JF; Lee M; Hogg A; Januszewicz H; Wolf M; Prince HM; Macmanus M; Hicks RJ
Leuk Lymphoma; 2007 Mar; 48(3):596-600. PubMed ID: 17454604
[TBL] [Abstract][Full Text] [Related]
44. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
45. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
[TBL] [Abstract][Full Text] [Related]
46. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.
Broecker-Preuss M; Becher-Boveleth N; Müller SP; Hüttmann A; Hanoun C; Grafe H; Richter J; Klapper W; Rekowski J; Bockisch A; Dührsen U
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2611-2621. PubMed ID: 34708297
[TBL] [Abstract][Full Text] [Related]
47. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
48. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
49. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.
Kobe C; Dietlein M; Hellwig D
Semin Nucl Med; 2018 Jan; 48(1):28-36. PubMed ID: 29195615
[TBL] [Abstract][Full Text] [Related]
50. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
51. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
52. Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance.
Suh KJ; Kim KH; Kim R; Byun JM; Kim M; Park JH; Keam B; Kim TM; Kim JS; Choi IS; Heo DS
Korean J Intern Med; 2019 Jul; 34(4):894-901. PubMed ID: 29466847
[TBL] [Abstract][Full Text] [Related]
53. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy.
Coughlan M; Elstrom R
Cancer Imaging; 2014 Nov; 14(1):34. PubMed ID: 25608713
[TBL] [Abstract][Full Text] [Related]
54. Simultaneous breast cancer and DLBCL lymphoma - role of PET/CT examination with 18F-FDG and 18F-FES.
Hołody Ł; Kunikowska J; Braziewicz J
Nucl Med Rev Cent East Eur; 2018; 21(2):113-114. PubMed ID: 29956818
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma.
Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS
Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889
[TBL] [Abstract][Full Text] [Related]
56. [Prognostic value of maximum standard uptake on pretreatment 18F-FDG PET/CT scan in newly diagnosed diffuse large B cell lymphoma].
Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3246-9. PubMed ID: 23328506
[TBL] [Abstract][Full Text] [Related]
57. Combined positron emission tomography/computed tomography for diagnosis and monitoring of orbital adnexal lymphoma.
Klingenstein A; Garip-Kuebler A; Mueller-Lisse UG; Hintschich C
Acta Ophthalmol; 2018 Sep; 96(6):e712-e717. PubMed ID: 30146694
[TBL] [Abstract][Full Text] [Related]
58. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
[TBL] [Abstract][Full Text] [Related]
59. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
60. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?
Yeoh KW; Mikhaeel NG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):14-20. PubMed ID: 22578540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
